{'fraction_non_alphanumeric': 0.015426497277676952, 'fraction_numerical': 0.0, 'mean_word_length': 5.488235294117647, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Role of Growth Factors in Myoblast Transfer Therapy

Myoblast transfer therapy, despite unsatisfactory clinical trial results, is still a potential method for the rectification of primary muscle myopathies, provided the procedure can be significantly improved. The technique involves implanting donor myoblasts into diseased muscle by the injection of large numbers of these cells. The majority of transplanted myoblasts die and are rapidly removed following injection, which is believed to account for the low incorporation rates of donor myoblasts and the coincident short term expression of donor gene products. A major goal in this area of research is to enhance the levels of donor myoblast incorporation and consequently the duration of donor gene expression. Muscle growth factors are naturally occurring agents which have been shown to elicit strong actions on myoblast growth. The potential role for these factors, in particular, leukaemia inhibitory factor (LIF) and basic flbroblast growth factor (bFGF), in enhancing the efficacy of myoblast transfer therapy is discussed in this paper.